Treatment discontinuation in desmoid tumors: Factors associated with better outcomes after sorafenib discontinuation.
Yi I, Gomes P, Hardy N, Rose B, Yu-Cherng C, Bialick S, Jonczak E, D'Amato G, Deshpande H, Carmagnani Pestana R, David B, Trent J, Campos F, Costa P. Treatment discontinuation in desmoid tumors: Factors associated with better outcomes after sorafenib discontinuation. Journal Of Clinical Oncology 2025, 43: 11562-11562. DOI: 10.1200/jco.2025.43.16_suppl.11562.Peer-Reviewed Original ResearchDesmoid tumorsMedian TFSPatients treated with sorafenibMulti-institutional retrospective analysisPalmar-plantar erythrodysesthesia syndromeSide effectsDuration of sorafenib treatmentDuration of systemic therapyFuture treatmentPatient stopped therapyOutcomes of patientsLog-rank testKaplan-Meier curvesTime of discontinuationFactors associated with better outcomesMonths of durationProgression of diseaseDiscontinued sorafenibSorafenib discontinuationSorafenib useStable diseasePartial responseDiscontinued therapySystemic therapyTreatment discontinuation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply